Development-Stage IPOs in 2002

2002's IPOs ranked by price-to-sales.

Most of the IPOs successfully completed on US exchanges this year were companies that were already revenue positive, or even profitable. Companies like Hexal AG division Eon Labs Inc. , American BioScience Inc. 's American Pharmaceutical Partners Inc. and CTI Molecular Imaging Inc. —which have achieved the largest IPO valuations this year—all have healthy businesses based on real sales from real products [See Deal], [See Deal], [See Deal]. But some investors are still willing to take more of a flyer—albeit at modest prices and with companies at least close to fulfilling their product ambitions. To isolate these, in the chart below, we've ranked the US IPOs to date in 2002 by price-to-sales—the higher the P/S, the greater an investor's bet on the future.

By this logic, the highest anticipated value company—though one of the lower-value companies in market cap—was monitoring device company HealtheTech...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By 

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.